/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

KEZAR LIFE SCIENCES INC Share Price Today: Live Updates & Key Insights

KEZAR LIFE SCIENCES INC share price today is $7.22, up 2.28%. The stock opened at $7.16 against the previous close of $7.02, with an intraday high of $7.18 and low of $7.14.

KEZAR LIFE SCIENCES INC Share Price Chart

style
pb-0

KEZAR LIFE SCIENCES INC

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0

KEZAR LIFE SCIENCES INC Share Price Performance

$7.22 0.0228(2.28%) KZR at 13 Mar 2026 01:54 PM Biotechnology
Lowest Today 7.14
Highest Today 7.18
Today’s Open 7.16
Prev. Close 7.02
52 Week High 7.45
52 Week Low 3.53
Day’s Range: Low 7.14 High 7.18
52-Week Range: Low 3.53 High 7.45
1 day return -
1 Week return -
1 month return +13.64
3 month return +15.28
6 month return +91.62
1 year return +24.43
3 year return +39.9
5 year return +13.28
10 year return -

KEZAR LIFE SCIENCES INC Institutional Holdings

BML Capital Management LLC 9.85

TANG CAPITAL MANAGEMENT LLC 9.84

Suvretta Capital Management, LLC 9.80

Vanguard Group Inc 4.67

Nantahala Capital Management, LLC 3.78

Affinity Asset Advisors, LLC 3.13

Vanguard Total Stock Mkt Idx Inv 3.05

Orbimed Advisors, LLC 2.63

Stonepine Capital Management Llc 2.13

Acadian Asset Management LLC 1.83

Renaissance Technologies Corp 1.79

Peapod Lane Capital LLC 1.73

ADAR1 Capital Management LLC 1.61

Ikarian Capital, LLC 1.46

BlackRock Inc 1.34

Qiming U.S. Ventures Management, LLC 1.13

Aldebaran Capital LLC 1.10

Vanguard Institutional Extnd Mkt Idx Tr 0.92

Geode Capital Management, LLC 0.90

Bridgeway Capital Management, LLC 0.71

Bridgeway Ultra-Small Company 0.71

Fidelity Extended Market Index 0.47

Shay Capital LLC 0.46

RBF LLC 0.38

iShares Micro-Cap ETF 0.22

Dimensional US Small Cap ETF 0.17

Blackrock Extended Mkt Fund CF 0.17

Fidelity Total Market Index 0.15

Extended Equity Market Fund K 0.14

Northern Trust Extended Eq Market Idx 0.13

NT Ext Equity Mkt Idx Fd - L 0.13

Spartan Extended Market Index Pool F 0.12

Fidelity Global Micro-Cap F 0.12

Fidelity Series Total Market Index 0.11

Vanguard Balanced Index Inv 0.11

Vanguard Instl Ttl Stck Mkt Idx Tr 0.08

Spartan Total Market Index Pool G 0.06

NT Ext Equity Mkt Idx Fd - NL 0.06

DFA US Micro Cap I 0.05

NT Ext Eq Mkt Indx Fd DC Lending Tier 5 0.05

KEZAR LIFE SCIENCES INC Market Status

Strong Buy: 3

Buy: 0

Hold: 3

Sell: 0

Strong Sell: 0

KEZAR LIFE SCIENCES INC Fundamentals

Market Cap 51.41 M

PB Ratio 0.6196

PE Ratio 0.0

Enterprise Value -28.90 M

Total Assets 144.68 M

Volume 32430

KEZAR LIFE SCIENCES INC Company Financials

Annual Revenue FY23:7000000 7.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:0 0.0M, FY19:0 0.0M

Annual Profit FY23:null 0.0M, FY22:null 0.0M, FY21:null 0.0M, FY20:null 0.0M, FY19:null 0.0M

Annual Net worth FY23:-87791000 -87.8M, FY22:-65316000 -65.3M, FY21:-53279000 -53.3M, FY20:-38990000 -39.0M, FY19:-31531000 -31.5M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:-227000 -0.2M, Q2/2025:null 0.0M, Q1/2025:-251000 -0.3M, Q3/2024:null 0.0M, Q2/2024:-261000 -0.3M

Quarterly Net worth Q3/2025:-11227000 -11.2M, Q2/2025:-13704000 -13.7M, Q1/2025:-16556000 -16.6M, Q3/2024:-20313000 -20.3M, Q2/2024:-21547000 -21.5M

About KEZAR LIFE SCIENCES INC & investment objective

Company Information Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b/2 clinical trials in systemic lupus erythematosus. It is also developing KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Organisation Biotechnology

Employees 55

Industry Biotechnology

CEO Dr. Christopher J. Kirk Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow